Skip to content

Study · Animal study (in vivo) · mouse · 2006

5 results

Naloxone-blocked depriming effect of anxiolytic selank on apomorphine-induced behavioral manifestations of hyperfunction of dopamine system.

Meshavkin VK, Kost NV, Sokolov OY, Zolotarev YA, Myasoedov NF, Zozulya AA

Bulletin of experimental biology and medicine1 Nov 2006Cited by 1 (Europe PMC)

PMID17415472 (opens in a new tab)DOI10.1007/s10517-006-0428-1 (opens in a new tab)PepBankPUB-17415472
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intraperitoneal Selank at 0.01 to 10.0 mg/kg reduced behavioral manifestations of dopamine system hyperfunction induced by apomorphine in the verticalization test.

    In plain wordsIn mice, Selank reduced behaviours caused by apomorphine, a drug that overstimulates the dopamine system.

    Peptide
    Selank
    Outcome
    DecreaseApomorphine-induced dopamine-system behavior (verticalization)
    Study

    mousen: not reported in source

    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    0.01, 0.1, 1.0 and 10.0 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Peptide anxiolytic selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) applied intraperitoneally in doses of 0.01, 0.1, 1.0, and 10.0 mg/kg to mice reduces behavioral manifestations of dopaminergic system induced by apomorphine in the verticalization test.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, the Selank effect on apomorphine-induced behavior was comparable to that of olanzapine at near-therapeutic doses of 0.1 and 1.0 mg/kg.

    In plain wordsIn mice, the effect of Selank on apomorphine-induced behaviour was comparable to that of the antipsychotic olanzapine.

    Peptide
    Selank
    Outcome
    No significant changeApomorphine-induced behavior versus olanzapine
    Study

    mousen: not reported in source

    Comparator
    Olanzapine
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    0.01, 0.1, 1.0 and 10.0 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    This effect was comparable to that of atypical antipsychotic olanzapine in near-therapeutic doses (0.1 and 1.0 mg/kg, intraperitoneally)
    1 context sentence
    Summary · context
    Peptide anxiolytic selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) applied intraperitoneally in doses of 0.01, 0.1, 1.0, and 10.0 mg/kg to mice reduces behavioral manifestations of dopaminergic system induced by apomorphine in the verticalization test.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice, the Selank effect on apomorphine-induced behavior was blocked by the nonselective opioid receptor antagonist naloxone (10 mg/kg).

    In plain wordsIn mice, the opioid blocker naloxone stopped the effect of Selank on apomorphine-induced behaviour.

    Peptide
    Selank
    Outcome
    Not applicableBlockade of Selank effect by naloxone
    Study

    mousen: not reported in source

    Comparator
    Naloxone 10 mg/kg
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    0.01, 0.1, 1.0 and 10.0 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    was blocked with nonselective opioid receptor antagonist naloxone (10 mg/kg, intraperitoneally).
    1 context sentence
    Summary · context
    Peptide anxiolytic selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) applied intraperitoneally in doses of 0.01, 0.1, 1.0, and 10.0 mg/kg to mice reduces behavioral manifestations of dopaminergic system induced by apomorphine in the verticalization test.
  4. 04LabIn vitro (cell-free)Activity measurement

    In a radioreceptor assay on rat brain membranes, Selank did not displace the D2-dopamine receptor antagonist 3H-spiperone (EC50 above 100 microM).

    In plain wordsIn lab tests on rat brain membranes, Selank did not displace a dopamine D2 receptor blocker from its binding sites.

    Peptide
    Selank
    Outcome
    No significant changeDisplacement of 3H-spiperone from D2-dopamine receptor sites
    Study

    ratn: not reported in source

    rat brain membranes, radioreceptor assay
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    EC50
    > 100 microM
    3H-spiperone, rat brain membranes

    Source sentences

    Summary
    Radioreceptor assay showed that selank did not displace nonselective D2-dopamine receptor antagonist (3)H-spiperone (EC50>100 microM)
  5. 05LabIn vitro (cell-free)Activity measurement

    In a radioreceptor assay on rat brain membranes, Selank did not displace the delta- and micro-opioid receptor ligand 3H-DADLE (EC50 above 40 microM).

    In plain wordsIn lab tests on rat brain membranes, Selank did not displace an opioid receptor ligand from its binding sites.

    Peptide
    Selank
    Outcome
    No significant changeDisplacement of 3H-DADLE from opioid receptor sites
    Study

    ratn: not reported in source

    rat brain membranes, radioreceptor assay
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    EC50
    > 40 microM
    3H-DADLE, rat brain membranes

    Source sentences

    Summary
    Radioreceptor assay showed that selank did not displace nonselective D2-dopamine receptor antagonist (3)H-spiperone (EC50>100 microM) and delta- and micro-opioid receptor ligand 3H-DADLE (EC50>40 microM) from specific binding sites on rat brain membranes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.